I need help! l l Searching for Diabetes Type 2 patients l l Drug Naïve l l New category of oral agent l l Clinical outpatient trial l l me:

Slides:



Advertisements
Similar presentations
Inpatient Hyperglycemia Management
Advertisements

In-Patient Management of Hyperglycemia Rey Vivo, MD Assistant Professor of Medicine Texas Tech University Health Sciences Center.
University of Minnesota – School of Nursing Spring Research Day Glycemic Control of Critically Ill Patients Lynn Jensen, RN; Jessica Swearingen, BCPS,
DIABETES Cameron VanTassell MS,RD,BC-ADM. HbA1c Definition-a stable glycoprotein formed when glucose binds to hemoglobin A in the blood in a concentration.
Introducing The SHINE Trial (Stroke Hyperglycemia Insulin Network Effort) An Overview for Clinical Nurses NIH-NINDS U01 NSO69498.
BLOOD GLUCOSE CONTROL A learning module for Staff.
Atlanta Diabetes Associates Original Title A SEMI-CLOSED LOOP INTRAVENOUS INSULIN ALGORITHM, SHOWN TO BE SAFE, SIMPLE, AND EFFECTIVE IN 82,078 HOURS OF.
Management of Hyperglycemia and Diabetes in the Hospital: Case Studies
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
MMI Task Force on Diabetes House Staff Curriculum.
Canadian Diabetes Association Clinical Practice Guidelines In-Hospital Management of Diabetes Chapter 16 Robyn Houlden, Sara Capes, Maureen Clement, David.
Glycemic Control in Acutely Ill Patients Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard Medical School Senior Vice President for.
Diabetes Management in Hospital November 16, 2003 Endocrine Fellows Conference Paul C. Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
INPATIENT DIABETES GUIDE Ananda Nimalasuriya M.D..
INSULIN STRATEGIES IN TYPE 2 DIABETES. The epidemic of type 2 diabetes and the recognition that achieving specific glycemic goals can substantially reduce.
Correction Insulin for Inpatient Hyperglycemia Estelle Lin June 2012.
Analogs as a Focus Bruce W. Bode, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Insulin therapy.
Afrezza® – inhaled human insulin
Therapeutic Options Insulins. 1 Insulin Preparations ClassAgents Human insulinsRegular, NPH, lente, ultralente Insulin analoguesAspart, glulisine, lispro,
Management of Inpatient Blood Glucose at Temple Housestaff Orientation 2014.
Diabetes Management in the Hospital: Case Studies Bruce W. Bode, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Sugar control in Critical care unit Senior clinical pharmacist : Lihua Fang Koo Foundation Cancer Center.
Glycemic Control for myocardial infraction. Why??????
The Patient Undergoing Surgery: Proven Steps to Better Outcomes Ariel U. Spencer, MD Lafayette Surgical Clinic Lafayette, Indiana.
Intensive versus Conventional Glucose Control in Critical Ill Patients N Engl J Med 2009; 360: 雙和醫院 劉慧萍藥師.
Module 3 Initial Recognition, Triaging, and Management of Hyperglycemia Diabetes Special Interest Group Georgia Hospital Association.

Diabetes Management in Hospital Orlando, May 31, 2003 Paul C. Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Cardiovascular Disease & Mortality in Diabetes Stephen Fava MD, MRCP(UK), FEFIM, FACP, FRCP (Lond), MPhil (Malta), PhD (Exeter) Consultant Physician, Diabetologist.
Diabetes Management in the Hospital Bruce W. Bode, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Titrating Insulin to Glycemic Target Judy Bowen, MD CIM Rotation September, 2006.
Basal and Meal Time Insulin Case Study
MANAGEMENT OF THE HOSPITALIZED TYPE I DIABETIC PATIENT Riverside Methodist Hospital January 23, 2014 Rundsarah Tahboub, MD.
Inpatient Glycemic Management
Combination Therapy for Type 2 Diabetes Springfield, IL, Nov 15, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Basal Bolus: The Strategy for Managing All Diabetes Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia Presented in San Antonio, May.
Improving Patient Outcomes GLYCEMIC CONTROL IN PERI-OPERATIVE PATIENTS UTILIZING INSULIN INFUSION PROTOCOLS.
Diabetes Management in the Hospital Bruce W. Bode, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
EVALUATION OF CONVENTIONAL V. INTENSIVE BLOOD GLUCOSE CONTROL Glycemic Control in Critically Ill Patients DANELLE BLUME UNIVERSITY OF GEORGIA COLLEGE OF.
Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Toujeo® and it’s Place in Therapy
دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد INSULIN THERAY IN TYPE 1 DIABETES.
Module 41 Module 4 Pharmacologic Management of Hyperglycemia in the Hospital Part 1: Understanding How to Use Insulin Diabetes Special Interest Group Georgia.
Combination Therapy for Type 2 Diabetes Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia Presented in Dalton, GA on Aug 14, 2003.
Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA Part 4.
Postoperative Glucose Control and SCIP Measures Gorav Ailawadi, MD Chief, Adult Cardiac Surgery University of Virginia April 25, 2015.
Achieving Glycemic Control in the Hospital Setting Part 1 of 3
Intensive Management of Inpatient Hyperglycemia Nicole L. Artz, MD
Achieving Glycemic Control in the Hospital Setting (Part 2 of 4)
Insulin Pump Therapy Bruce W. Bode, MD and Sandra Weber, MD.
Achieving Glycemic Control in the Hospital Setting
Glycemic Control In The Hospital Setting. LOYOLA UNIVERSITY MEDICAL CENTER Total Number of Beds 580 LOCATION: ICU # OF BEDS MICU 15 CCU 10 Heart Transplant.
ADDITIONAL SLIDES FOR ASSIST WITH COMPREHENSION OF LAB CONTENT-MODULE FIVE-DM DENISE TURNER, MS-N.ED, RN, CCRN.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Special Situations In The Management Of In-Patient Hyperglycemia
Strategies to Reduce Hypoglycemia Presented by: Hennie Garza, M.S., R.Ph., C.D.E, Director of Pharmacy Utilization and Outcomes Senior Care Centers
Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
Inpatient Glycemic Management
EndoTool IV Physician User Guide Content Expert:
Management of diabetes mellitus in hospitalized patients
Insulin Delivery Systems Atlanta Diabetes Associates
T1DM: Insulin Initiation
Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures 
Managing Hypoglycemia & Hyperglycemia
PowerPoint 16:9 Screen Ratio Template *
Insulin Delivery Systems Atlanta Diabetes Associates
Inpatient Insulin Management on the Wards
Presentation transcript:

I need help! l l Searching for Diabetes Type 2 patients l l Drug Naïve l l New category of oral agent l l Clinical outpatient trial l l me: l l Call me

Diabetes Management in the Hospital Shannon Oates Endocrinology Arnett Clinic

Today l Money l Mortality l Morbidity l Math (I love algebra)

Diabetes in Hospitalized Patients Million US Hospitalizations 15% of Admissions 14 Million Hospital Days 20% of All Hospital Days 36% First Diagnosed in Hospital 66% No Documentation by Physician 27% Labeled Hyperglycemia 2% Diagnosed on Chart

Diabetes in Hospitalized Patients 1997 Costs $ 23,500 Each Diabetes Patient vs.$ 23,500 Each Diabetes Patient vs. $12,200 for Non-Diabetes Patient $12,200 for Non-Diabetes Patient 60% of All Diabetes-Related Costs60% of All Diabetes-Related Costs Only 5% DKA, HHNKCOnly 5% DKA, HHNKC 48% Diabetes Complications48% Diabetes Complications 52% Other Conditions52% Other Conditions

Diabetes in Hospitalized Patients Reason for Higher Costs l Higher Rate of Hospitalization l Longer Stays l More Procedures, Medications l Chronic Complications l More Arteriosclerotic Disease l More Infections l Complicated Pregnancies

Diabetes in Hospitalized Patients High-risk for Bacterial Infection –Surgery –Catheters –Intravenous Access –Anesthesia Problems with wound healing Problems with tissue and organ perfusion

Infectionsin Diabetes Infections in Diabetes More Frequent l Bacteremia l Septic Shock l Pyelonephritis l Candida Unique l Necrotizing Fasciitis l Fournier’s Gangrene l Mucormycosis l Malignant External Otitis

Mucormycosis above Necrotising fasiitis right

Infections in Diabetes l One BG >220 mg/dl results in 5.8 times increase in nosocomial infection rate l Two hours hyperglycemia results in impaired WBC function for weeks Pomposelli, New England Deaconess, J Parenteral and Enteral Nutrition 22:77-81,1998

Side Effects of BG >200 mg/dl l Reduced Intravascular Volume l Dehydration l Electrolyte Fluxes l Impaired WBC Function l Immunoglobulin Inactivation l Complement Disabling l Increased Collagenase, Decreased Wound Collagen

Psychology of Diabetes in Hospital l Patients expect good glycemic control as part of hospital care l They strive for recommended goals at home l Difficult to understand staff’s casual approach to BG’s >200

Evidence for Immediate Benefit of Normoglycemia in Hospitalized Patients l Numerous Publications on in Vitro Evidence –Neutrophil Dysfunction –Complement Inhibition –Altered Redox State (Pseudohypoxia) l Six Recent Clinical Publications supporting good glucose control in the hospital setting

Open Heart Surgery in Diabetes Portland St. Vincent Medical Center Control Group l N=968 l l SubQ Insulin q 4 h l Goal 200 mg/dl l Standard Deviation 36 l All Mean BG’s <200 47% Study Group l l N=1499 l l l l IV Insulin l l Goal mg/dl l l Standard Deviation 26 l l All Mean BG’s <200 84% Furnary et al, The 34th Meeting of The Society of Thoracic Surgeons New Orleans, LA January 26, 1998

Open Heart Surgery in Diabetes Portland CII Protocol Demographics l Total Open Heart Surgery Patients 14,468 l Diabetes at Admission 2467 (17%) l Age 65 SD 10 l Males 62% l Insulin Rx 36% l Oral diabetes agent 48%

Open Heart Surgery in Diabetes Portland St. Vincent Medical Center Perioperative Blood Glucose Furnary et al, The 34th Meeting of The Society of Thoracic Surgeons New Orleans, LA January 26, 1998

Incidence of DSWI: CII Furnary, et al, The 34th Meeting of The Society of Thoracic Surgeons New Orleans, LA January 26, 1998

Open Heart Surgery in Diabetes Portland CII Protocol Infectious Complications Diabetes l 31/2467 (1.3%) Deep Sternal Wound Infection (DSWI) 23/31 Required Second Admission 22 Micrococcus 0 Anaerobes, fungal, yeast 0 Anaerobes, fungal, yeastNon-Diabetes l 40/12,005 (0.3%)

Open Heart Surgery in Diabetes Portland CII Protocol Mortality l All(99/2467) 4.0% l SQI 6.1% l CII 3.0% l DSWI 19.0% l No DSWI 3.8% Recent Experience l DSWI as in non-diabetics l No DSWI in last 15 mo. SQI= subcutaneous insulin CII= continuous insulin infusion DSWI=deep sternal wound infection

Open Heart Surgery in Diabetes Portland CII Protocol Comparison of Groups Higher Risk Patients in CII Group

Open Heart Surgery in Diabetes Portland CII Protocol Univariate Analysis of DSWI

VariableSQICIISavings # DSWI2, ,959 Additional LOS47,48816,41631,342 Additional $$78.4M$26.6M$51.7M # Deaths Estimated USA Socioeconomic Savings Assumes 742K cases*, 20% prevalence of DM & 2% DSWI with SQI *1998 Heart & Stroke Statistical update, AHA

Open Heart Surgery in Diabetes Portland CII Protocol Weakness of Study l Not Randomized l Temporal Sequential Nature l Subtle Cumulative Improvements in Techniques

Open Heart Surgery in Diabetes Portland CII Protocol Conclusions l Magnitude and Strength of Study is Compelling l Ethics of Confirming Study Would be Questionable l Application of CII (continuous insulin infusion) is Simple and Safe l Hyperglycemia Predicts DSWI l CII Prevents DSWI

Open Heart Surgery in Diabetes John Hopkins l Prospective Cohort Study of 411 OHS pts with Diabetes 1990 – 1995 l Diabetes based on history (42% insulin treated, 45% oral agents) l SMBG 4x/day with sliding scale l Examined relationship between peri-operative glucose control and risk of all infections

Open Heart Surgery in Diabetes John Hopkins l 24.3% with infections l BG divided into quartiles Relative Odds Q % Q % 1.17 Q % 1.86* Q % 1.72* Golden SH Diabetes Care 22: 1408, 1999 * P < 0.01

DIGAMI Study Diabetes, Insulin Glucose Infusion in Acute Myocardial Infarction(1997) l Acute MI With BG > 200 mg/dl l Intensive Insulin Treatment l IV Insulin For > 24 Hours l Four Insulin Injections/Day For > 3 Months l Reduced Risk of Mortality By: 28% Over 3.4 Years 51% in Those Not Previous Diagnosed Malmberg BMJ 1997;314:1512

Cardiovascular Risk Mortality After MI Reduced by Insulin Therapy in the DIGAMI Study Malmberg, et al. BMJ. 1997;314: All Subjects (N = 620) Risk reduction (28%) P =.011 Standard treatment Years of Follow-up 2345 Low-risk and Not Previously on Insulin (N = 272) Risk reduction (51%) P =.0004 IV Insulin 48 hours, then4 injections daily Years of Follow-up

ICU Survival l 1548 Patients (mostly OHS pts.) l All with BG >200 mg/dl l Randomized into two groups –All Maintained on IV insulin –Conventional group (BG ) –Intensive group (BG ) l Conventional Group had 1.74 X mortality Van den Berghe et al, NEJM 2001;345(19):1359

ICU IV Insulin Protocol (not DKA) l If > 100 mg/dl, 2 U/h If > 200 mg/dl, 4 U/h l If > 140 mg/dl, increase by 1 – 2 U/h l If 121 to 140 mg/dl, increase by 0.5 – 1 U/h l If 111 to 120 mg/dl, increase by 0.1 – 0.5 U/h l If 81 to 110 mg/dl, no change l If 61 to 80 mg/dl, change back to prior rate Van den Berghe et al, NEJM 2001;345(19):1359

ICU Survival Blood glucose control: Conventional Intensive Mean AM BG % Receiving Insulin 39% 100% BG < 40 mg/dl 6 39 Van den Berghe et al, NEJM 2001;345(19):1359

ICU Survival Intensive Therapy (80 to 110 mg/dL) resulted in: l 34% reduction in mortality l 46% reduction in sepsis l 41% reduction in dialysis l 50% reduction in blood transfusion l 44% reduction in polyneuropathy Van den Berghe et al, NEJM 2001;345(19):1359

Conclusion All hospital patients should have normal glucose

Insulin The agent we have to control glucose most powerful

Methods For Managing Hospitalized Persons with Diabetes l Continuous Variable Rate IV Insulin Drip Major Surgery, NPO, Unstable, MI, DKA, Hyperglycemia, Steroids, Gastroparesis l Basal / Bolus Therapy when eating l Teach them insulin injections

IV insulin protocol l Not as intuitive as the Van den Berghe l More agile in response to rate of change of blood sugars l We do have a version of Van den Berghe available in the ICU

Continuous Variable Rate IV Insulin Drip l 25 units Regular Insulin into 250 cc NS –(0.1 unit/cc) l Starting Rate Units / hour = (BG – 60) x 0.02 –BG is current Blood Glucose and 0.02 is the multiplier l Check glucose every hour and adjust drip l Adjust Multiplier to keep in desired glucose target range (100 to 140 mg/dl)

Continuous Variable Rate IV Insulin Drip l Adjust Multiplier (initially 0.02) to obtain glucose in target range 100 to 140 mg/dL If BG > 140 mg/dL, increase by 0.01 If BG < 100 mg/dL, decrease by 0.01 If BG 100 to 140 mg/dL, no change in Multiplier l If BG is < 80 mg/dL, give D50 (one to three cc) l Once eating, continue drip till 1 hour post SQ insulin

Example l Initial glucose of 200: drip starts at 2 units per hour l Glucose drops to 90, decrease drip to 0.6 units per hour l If glucose instead rose to 210, the drip increases to 4.5 units per hour

4: :0012:0016:0020:0024:004:00 BreakfastLunchDinner Plasma insulin (U/ml) Plasma insulin ( µ U/ml) Time 8:00 Physiological Serum Insulin Secretion Profile

Comparison of Insulins Insulin Onset ofDuration of preparations action Peak action Regular30–60 min2–4 h6–10 h Lispro/aspart5–15 min1–2 h 4–6 h NPH 1–2 h4–8 h10–18 h Lente 1–2 h6–8 h12–20 h Ultralente2–4 hUnpredictable16–20 h Glargine1–2 hFlat~24 h

4:0016:0020:0024:004:00 BreakfastLunchDinner 8:00 12:008:00 Time Glargine or Detemir Lispro Lispro Lispro Aspart Aspart Aspart or Plasma insulin Basal/Bolus Treatment Program with Rapid-acting and Long-acting Analogs

Lepore, et al. Diabetes. 1999;48(suppl 1):A Time (h) after SC injection End of observation period 2030 Glargine NPH Glucose utilization rate (mg/kg/h) Glargine vs NPH Insulin in Type 1 Diabetes Action Profiles by Glucose Clamp

Correction Bolus—Rule of 1500 l Must determine how much glucose is lowered by 1 unit of short- or rapid-acting insulin l This number is known as the correction factor (CF) l Use the 1500 rule to estimate the CF l CF = 1500 divided by the total daily dose (TDD) ex: if TDD = 30 units, then CF = 1500/30 = 50 meaning 1 unit will lower the BG ~50 mg/dl

Correction Bolus Formula Example: –Current BG:220 mg/dl –Ideal BG: 100 mg/dl –Glucose Correction Factor: 50 mg/dl Current BG - Ideal BG Glucose Correction factor =2.4u

How to Initiate MDI l Starting dose = 0.4 to 0.5 x weight in kilograms l Bolus dose (aspart/lispro) = 20% of starting dose at each meal l Basal dose (glargine/NPH) = 40% of starting dose given at bedtime or anytime l Correction bolus = (BG - 100)/ Correction Factor (CF = 1500/total daily dose)

How to Initiate MDI-example l starting dose = 0.45 x wgt. in kg l Wt is 110 kg; 0.45 x 110 = 50 units l Basal dose (glargine) = 40% of starting dose at HS; 0.4 x 50 = 20 units at HS l Bolus dose (aspart / lispro) = 20% of starting dose at each meal; 0.2 x 50 = 10 units ac (t.i.d.) l Correction bolus = (BG - 100)/ CF, where CF = 1500/total daily dose; CF = 30

Correction Bolus Formula Example: –Current BG:250 mg/dl –Ideal BG: 100 mg/dl –Glucose Correction Factor: 30 mg/dl Current BG - Ideal BG Glucose Correction factor =5.0u

Diabetes Plan What Can We Do For Patients Admitted To Hospital? Diabetes Plan What Can We Do For Patients Admitted To Hospital? Finger Stick BG ac q.i.d. on ALL Admissions l Do Not Use Sliding Scale As Only Diabetes Management l Check All Steroid Treated Patients l Diagnose Diabetes FBG >126 mg/dl Any BG >200 mg/dl

Diabetes Plan What Can We Do For Patients Admitted To Hospital? Diabetes Plan What Can We Do For Patients Admitted To Hospital? l Get Diabetes Education Consult l Do an A1C l Instruct Patient in Monitoring and Recording l See That Patient Has Meter on Discharge l Decide on Case Specific Program for Discharge l Arrange Early F/U with PCP l Do Not Use Sliding Scale As Only Diabetes Management

Diabetes at Hospital Conclusions l Any BG >200 mg/dl Is Diabetes (Fasting >126 mg/dl) l Most Diabetes Is Type 2 l All DM patients Must Self-Monitor BGs and Record l No BG >150 mg/dl Should Go Untreated l Most Hospitalized DM Patients Should Be on Insulin l IV Insulin is Most Effective, Efficient, Safest Rx in Acute Illness

Diabetes at Hospital Conclusions 2 l Type 2 Diabetes is Resistant to Insulin Reaction l Do Not Hold Insulin for Normal BG l A1C Values >7% Indicates Sub-optimal Care

Diabetes at Hospital Conclusions 3 l Discharge Plan For BG Control l You Are the Link Between the Best Diabetes Care and the Patient l Use Your Diabetes Resources Regional Diabetes Center Endocrinologists

The Paradigm for the Millenium Hyperglycemia: A Mortal Sin A blood glucose over 200 in a hospitalized patient causes increased morbidity and mortality. In the 21st Century Neglecting a BG >200 May Be Malpractice

Conclusion Intensive therapy is the best way to treat patients with diabetes

QUESTIONS l m m l l Thanks to Dr. Bruce Bode

I need help! l l Searching for Diabetes Type 2 patients l l Drug Naïve l l New category of oral agent l l Clinical outpatient trial l l me:

TPN In Diabetes VA Cooperative Trial l Benefit Negated l Increased Infections l Related to Hyperglycemia Buzby et al. NEJM 325: , 1991

GlyThrGluPheTyrProLysThr GlyThrGluPheTyrProLysThr Insulin Detemir (CH 2 ) 4 NH CO R Primary Structure of Lys(B29)-N-  - Tetradecanoyl, Des(B30)-Insulin

61 Brunner GA, et al. Exp Clin Endocrinol Diabetes. 2000;108: Elapsed time (min) Detemir-high Detemir-low Placebo Glucose infusion rate (mg/kg/min) Insulin Detemir in Nondiabetic Subjects— Pharmacokinetics by Glucose Clamp